

FORM PTO-1380 (REV. 10-2003)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER ABB10043P0013US	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. 10/552842 <small>✓</small>	
INTERNATIONAL APPLICATION NO. PCT/EP2004/003872		INTERNATIONAL FILING DATE 04.13.2004		PRIORITY DATE CLAIMED 04.14.2003	
TITLE OF APPLICATION: N-[(piperazinyl)hetaryl]arylsulfonamide Compounds with Affinity for the Dopamine D ³ Receptor					
APPLICANT(S) FOR DO/EO/US: Abbott GmbH & Co. KG.					
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected. (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <div style="margin-left: 20px;"> <input type="checkbox"/> is attached hereto <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). </div> 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated to the International Bureau c. <input type="checkbox"/> have not been made; however, the time for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or unexecuted declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A preliminary amendment. 14. <input checked="" type="checkbox"/> An Application Data Sheet. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power or attorney and/or change of address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. (154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items of information. A copy of the application as published; PCT/ISA/210 (January 2004) 					

U.S. APN 10/552842		INTERNATIONAL APPLICATION NO. PCT/EP2004/003872		ATTORNEY DOCKET NUMBER ABB10043P0013US	
21. The following fees are submitted				Applicant Use	Office Use Only
<input type="checkbox"/> a) Basic national fee \$300.00				\$ 300.00	
<input type="checkbox"/> b) Examination fee \$200.00				\$ 200.00	
<input type="checkbox"/> c) Search fee \$500.00				\$	
TOTAL OF ABOVE CALCULATIONS = \$1,000.00				\$ 500.00	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250.00 for each additional 50 sheets of paper or fraction thereof					
Total Sheets	Extra Sheets	Number of Additional 50 or fraction thereof (round up to a whole number)	Rate		
- 100 =	/50		x \$250.00	\$	
Surcharge of \$130.00 for furnishing oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total Claims	29 -20 =	9	x \$50.00	\$ 450.00	
Independent claims	3 - 3 =	0	x \$200.00	\$	
Multiple Dependent Claim(s) (if applicable)		0	+ \$360.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE				\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$ 950.00	
Amount to be refunded:					\$
Amount to be charged:					\$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ 950.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge Deposit Account No. 23-0785 in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0785. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>					
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>					
Send Correspondence to:					
CUSTOMER NUMBER: 32116					
WOOD, PHILLIPS, KATZ, CLARK & MORTIMER Citigroup Center, Suite 3800 500 West Madison Street Chicago, Illinois 60661-2511 Telephone: (312) 876-1800 Facsimile: (312) 876-2020			<p><i>Martin L. Katz</i> Martin L. Katz, Reg. No. 25,811</p>		
			October 11, 2005		
			Date		

10/552842

JC20 Rec'd PCT/PTO 11 OCT 2005

Attorney Docket No.: ABB10043P0013US

Applicant: ABBOTT GmbH & Co. Kg.

For: N-[(piperazinyl)arylsulfonamide Compounds with Affinity
for the Dopamine D3 Receptor

Serial No.: PCT/EP/2004/003872

Filing Date: October 11, 2005

CERTIFICATE OF MAILING BY EXPRESS MAIL

I hereby certify that the enclosed **National Phase Application** and any other documents referred to as enclosed herein, are being deposited in an envelope with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.

Express Mail Label No.: 576545443 US

Date of Deposit: 10-11-05

Typed/Printed
Name of Person Signing: Stephanie Frain

Signature:

